Italia markets closed

Isoray, Inc. (ISR)

NYSE American - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
0,3856+0,0038 (+1,00%)
Alla chiusura: 03:56PM EST
0,3900 +0,00 (+1,14%)
Dopo ore: 06:23PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,3818
Aperto0,3850
Denaro0,3850 x 800
Lettera0,3900 x 1100
Min-Max giorno0,3700 - 0,4059
Intervallo di 52 settimane0,1900 - 0,5100
Volume319.213
Media Volume310.738
Capitalizzazione54,799M
Beta (5 anni mensile)1,19
Rapporto PE (ttm)N/D
EPS (ttm)-0,0440
Prossima data utili06 feb 2023 - 10 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A1,00
  • GlobeNewswire

    Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

    RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.

  • GlobeNewswire

    Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

    Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PTRICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company w

  • GlobeNewswire

    Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

    RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpo